



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name: Tyrvaya

Page: 1 of 2

Effective Date: 3/16/2023

Last Review Date: 2/2023

Applies to:	<input type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input checked="" type="checkbox"/> Florida Kids
	<input checked="" type="checkbox"/> New Jersey	<input checked="" type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	<input type="checkbox"/> Texas

### Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Tyrvaya under the patient's prescription drug benefit.

### Description:

Tyvaya (varenicline solution) nasal spray is indicated for the treatment of the signs and symptoms of dry eye disease.

### Applicable Drug List:

Non-Formulary: Tyrvaya

### Policy/Guideline:

The requested drug will be covered with prior authorization when the following criteria are met:

- The request is not for continuation of therapy  
**AND**
- The requested drug is being prescribed for dry eye disease  
**AND**
  - The patient has experienced an inadequate treatment response to an artificial tears product  
**OR**
  - The patient has experienced an intolerance to an artificial tears product  
**OR**
  - The patient has a contraindication that would prohibit a trial of an artificial tears product  
**AND**
- The patient is unable to take cyclosporine ophthalmic emulsion for the given diagnosis due to a trial and inadequate treatment response or intolerance, or a contraindication  
**OR**
- The request is for continuation of therapy  
**AND**
- The requested drug is being prescribed for dry eye disease  
**AND**
- The patient achieved or maintained improvement in their signs and symptoms of dry eye disease from baseline, (e.g., ocular irritation, redness, mucous discharge, reduced visual function, ocular surface damage, reduced tear production)

Quantity Limits apply



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name: Tyrvaya Page: 2 of 2

Effective Date: 3/16/2023 Last Review Date: 2/2023

Applies to:	<input type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input checked="" type="checkbox"/> Florida Kids
	<input checked="" type="checkbox"/> New Jersey	<input checked="" type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	<input type="checkbox"/> Texas

**Approval Duration and Quantity Restrictions:**

**Approval:** 12 months

**Quantity Level Limit:** 2 nasal spray bottles (1 carton) per month

**References:**

1. Tyrvaya [package insert]. Princeton, NJ: Oyster Point Pharma, Inc, October 2021.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc.; 2021; Accessed October 29, 2021.
3. Preferred Practice Pattern. Dry Eye Syndrome. American Academy of Ophthalmology. November 2018.